XML 146 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) - USD ($)
1 Months Ended
Dec. 31, 2023
Oct. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Nov. 22, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Contract liabilities $ 0   $ 866,000    
GSK | GSK License Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Milestone payment receivable       $ 30,000,000  
Milestone payment receivable upon achievement of phase two and first patient dosed in phase three         $ 100,000,000
GSK | GSK License Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Commercial milestone payments at first commercial sale         190,000,000
Sales-related milestone payments         $ 590,000,000
GSK | GSK-HBV Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Initial transaction price 2,700,000        
Contract assets 0        
Contract liabilities $ 0        
GSK | GSK-HBV Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Development and sales milestone payments   $ 832,500,000